HOME > TOP STORIES

TOP STORIES

BUSINESS Shareholders Give Blessing to £46 Billion Shire Pact as Weber Touts US Foothold

December 6, 2018
BUSINESS Takeda Shareholders OK £46 Billion Shire Takeover

December 5, 2018
ORGANIZATION 9 EFPIA Companies Reviewed Headcount Planning after Drug Pricing Overhaul: Survey

December 5, 2018
BUSINESS Takeda Family Member Comes Forward for Final Appeal to Veto Shire Deal, but Admits Uphill Battle

December 4, 2018
BUSINESS With Current R&D Model Reaching Its Limit, Industry Going Digital to Boost Efficiency: Astellas Chairman

December 3, 2018
BUSINESS JT to Return Rights to Gilead’s 6 HIV Agents in 2019, Get 63.1 Billion Yen

November 30, 2018
BUSINESS Dissident Shareholder Group Hails Ex-Takeda Chief’s Opposition to Shire Deal

November 29, 2018
REGULATORY AMED Study Group Drafting Japan’s 1st Guidelines for Development of Recombinant Virus Vaccines

November 29, 2018
TRENDS Generic Industry at Crossroads: Companies Face Pressing Need to Boost Profitability ahead of FY2020

November 28, 2018
BUSINESS Keytruda Continues to Close in on Opdivo in July-September Global Sales

November 27, 2018
REGULATORY MHLW Proposes Introduction of Administrative Fines for Improperly Earned Revenues

November 27, 2018
BUSINESS Dissident Takeda Shareholders Making Final Pitch to Thwart Shire Buyout

November 26, 2018
REGULATORY MHLW Eyes Drastic Change to Cost Effective Analysis Flow, Enhanced Discussions Upfront

November 22, 2018
REGULATORY MHLW Proposes Quarterly Product Selections, Price Tweaks for CEA Scheme: Chuikyo

November 22, 2018
BUSINESS Pfizer’s ALK Inhibitor Lorbrena, Shire’s HAE Drug Now Available in Japan

November 21, 2018
BUSINESS Mitsubishi Tanabe Cuts FY2020 Targets in 5-Year Biz Plan on Flagging Royalty, Development Delay

November 21, 2018
BUSINESS 3 Japan Generic Majors Log 6% Growth in Combined April-September Sales despite Price Revision

November 20, 2018
BUSINESS 4 Major Wholesalers See 46.1% Increase in 1st Half Operating Profit due to Reductions in Yakkasa and SGA Costs

November 19, 2018
BUSINESS AstraZeneca Japan Set to Roll Out 4 New Treatments Every Year through 2021: Chief

November 16, 2018
REGULATORY Keytruda’s MSI-H Cancer Use Up for MHLW Panel Review Nov. 29; Wider Hemlibra Indication, 1st Line Tecentriq Also on Agenda

November 16, 2018

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

MHLW Floats Deducting Private-Practice Use for Re-Pricing, but Off-Cycle Cuts Possible; GLP-1 Eyed?

Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…

COMMENTARY

FY2026 Reform Debate for Drug Pricing Nears the Finish Line, Balance Needed

By Takashi Ebisawa

Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…

COLUMN

AI in HR: Navigating the Ethical Minefield

By Philip Carrigan

Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…